14 results about "Epitheliocyte" patented technology

The invention provides an application and a method for inducing phenotype transformation from oral mucosa epithelium to dry lip epithelium by linoleic acid, linoleic acid with proper concentration acts on oral mucosa epithelial cells to regulate and control cell differentiation procedures, so that expression of specific markers of the oral mucosa epithelial cells is reduced, expression of specific markers of dry lip epithelial cells is increased, and expression of the specific markers of the oral mucosa epithelial cells is increased. The directional transformation of the cell phenotype is realized. The linoleic acid with the proper concentration is 10-20 [mu] M. The linoleic acid has the effects of regulating keratinization index expression of mucous membrane epithelial cells and enhancing the mucous membrane tissue barrier function for the first time, and the function is not recognized in previous research and clinical application of the linoleic acid.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and / or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

The invention relates to a method for synchronously and quantitatively determining Atlantic salmon epithelial cells, Karenia mikimotoi and Vibrio parahaemolyticus in seawater, and belongs to the technical field of detection. Respectively adding the extracted eDNA into a reaction tube of an LAMP reaction system filled with a targeted Atlantic salmon marker gene Cytb, a Karenia mikimotoi marker gene ITS2 and a Vibrio parahaemolyticus marker gene tlh, and then putting the reaction tube into a full-automatic electronic gene amplification analyzer to obtain slopes kf, ka and kb of a linear fitting equation corresponding to a kinetic curve exponential phase, and substituting the Atlantic salmon epithelial cells, the Karenia mikimotoi and the vibrio parahaemolyticus into formulas LogNf = 52.96 kf + 0.27, LogNa = 88.13 ka-0.54 and LogNb = 70.79 kb < 2 > + 35.67 kb + 0.70, and respectively calculating the numbers Nf, Na and Nb of the Atlantic salmon epithelial cells, the Karenia mikimotoi and the vibrio parahaemolyticus in the detected seawater sample. According to the method, the number of target animal cells, algae cells and microbial cells can be synchronously obtained within 2 hours.

The present invention is directed to compositions for treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells by contacting orbital fat-derived mesenchymal cell with the damaged RPE cells.

The invention discloses a method for constructing a nasal mucosa epithelium single-layer model by using a single-cell digested organoid, and belongs to the technical field of bioengineering. The method comprises the following steps: firstly, carrying out digestion treatment, red blood cell lysis treatment, inoculated culture and passage on nasal mucosa tissues to obtain nasal mucosa organoid, then adding recombinase for dissociation to obtain dissociated epithelial cells, finally, planting the dissociated epithelial cells in a culture container subjected to coating treatment for incubation and adherence, and continuing to culture to obtain the nasal mucosa organoid. And preparing the nasal mucosa epithelium single-layer model. The multi-lineage differentiation potential and individual specificity of the organoid-derived cells are reserved, the cell adherence, passage and cryopreservation recovery stability is remarkably improved, the culture period is shortened, reagent expenditure and time cost are saved, and the defects that a traditional cell line is poor in physiological correlation, difficult in primary and gas-liquid interface culture acquisition, long in period and low in cost are overcome. And the three-dimensional organ-like chamber structure is not beneficial to top surface observation and solute transport research, so that the three-dimensional organ-like chamber structure is more suitable for scientific experiments.

The present invention relates to superoxide dismutase, and uses thereof for preventing or treating mucositis. The superoxide dismutase according to the present invention can be effectively used for treating or improving the inhibition of a proliferation of mucous epithelium cells, which is a side effect of anticancer agents or radiotherapy.

The invention discloses a medicine for treating renal fibrosis and application thereof, and the medicine for treating renal fibrosis comprises an inhibitor capable of inhibiting epithelial-mesenchymal transition of renal tubular epithelial cells HK-2 stimulated by TGF-beta1; the invention proves that the Kisspeptin analogue TAK-448 obviously improves the epithelial-mesenchymal transition of renal tubular epithelial cells HK-2 stimulated by TGF-beta1, and improves the renal fibrosis of UUO and FA mice, so that the Kisspeptin analogue TAK-448 has wide clinical application prospects, has huge potential in preparation of medicines for treating and / or improving renal fibrosis diseases, and can be used for preparing medicines for treating and / or improving renal fibrosis diseases. The industrial utilization value is high.

The present invention relates to the use of inhibitors or modulators of the SUMOylation pathway for use in a method of increasing or facilitating tissue regeneration in a mammal subject, such as a human subject in need thereof. In particular, the present invention relates to modulation of SUMOylation levels for use in the treatment of conditions associated to damaged intestinal epithelium, such as Crohn's disease and ulcerative colitis, in a mammal subject, such as a human subject in need thereof.

The invention provides application of fludarabine in preparation of a medicine for preventing and / or treating corneal epithelium lesion, and belongs to the technical field of biological medicine preparation. The invention discloses application of fludarabine in preparation of a medicine for preventing and / or treating corneal epithelium lesion. Experiments show that diabetes can cause increase of expression of STAT1 in corneal epithelium cells and delay healing of mouse corneal epithelium wounds, and the exogenous STAT1 antagonist fludarabine can reverse the healing delay phenomenon of diabetic mouse corneal epithelium wounds and promote repair of the corneal epithelium wounds. Therefore, the technical scheme provided by the invention provides a new treatment means for repairing the corneal epithelium lesion.

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and / or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

This determination device comprises a processor that acquires a Raman spectrum which has been detected by irradiating a gastrointestinal mucosal tissue with excitation light having a prescribed wavelength, that calculates, from the Raman spectrum in a first wavenumber band, a first feature amount which represents the state or amount of a substance contained in the mucosal epithelium, that determines the risk of future deterioration of the gastrointestinal mucosal tissue on the basis of the first feature amount, and that outputs the result of the determination. Thus, provided is a determination device which is capable of accurately determining the risk of future deterioration of a gastrointestinal mucosal tissue.

The invention relates to a preparation process of a polydimethylsiloxane injection surface for releasing a cell sheet and application of the polydimethylsiloxane injection surface in corneal reconstruction. The abstract content is inspired by a smooth surface of a pitcher plant flesh opening to trap insects into a bag. A scientist introduces smooth liquid as an unbonded coating into the surface of a porous material to achieve the purposes of resisting pollution, preventing dust, preventing adhesion growth of marine invertebrate organisms and preventing rust, the silica gel culture dish is researched, developed and prepared by referring to related data to solve the problem of cell sheet adhesion removal by applying the technology, and after modification, film coating, inoculated culture and adhesion removal treatment, the cell sheet adhesion removal effect is improved. After many times of failures, the corneal epithelium cell sheet is removed, the cell sheet is further identified to be a cell sheet with high survival rate and regeneration capacity, and animal corneal cell sheet transplantation experiments confirm that the transplanted cell sheet can be quickly decocted with the damaged corneal epithelium, so that the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium, and the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium. And a P63 labeled protein with regeneration characteristics is observed to exist in a cornea layer through tissue slice staining.

The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and / or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and / or intestinal tracts.